Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03850379 · ClinicalTrials.gov registry record · Phase 2
Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant
A Phase 2 study of Stem Cell Transplant Complications and Prophylaxis, sponsored by Henry Ford Health System.
- Completed
- Registry status
- Phase 2
- Development phase
- 308
- Enrollment target
- 1
- Study location
NCT03850379 is a Phase 2 study of Stem Cell Transplant Complications and Prophylaxis that has completed, run by Henry Ford Health System. The registered enrollment target is 308 participants, above the 165-participant average among 15 other Stem Cell Transplant Complications trials with a reported enrollment target (87% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03850379, a Phase 2 study of Stem Cell Transplant Complications and Prophylaxis, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 308 participants
- Enrollment target
- 1
- Study location
Study Summary
Ciprofloxacin and levofloxacin are both in guidelines to use for prophylaxis in autologous and allogeneic Stem cell transplant.Ciprofloxacin was recently replaced by levofloxacin as the preferred agent in some transplant centers. In some small retrospective studies ciprofloxacin prophylaxis was associated with a higher rate of breakthrough gram positive bloodstream infections. However, the optimum oral agent for antibacterial prophylaxis in transplant recipients remains uncertain.
Conditions Studied
Interventions
- DRUG Ciprofloxacin
- DRUG Levofloxacin
Study Locations (1)
Michigan
- Henry Ford - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2018-03-14 |
| Est. Completion | 2024-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03850379
The ClinicalTrials.gov registry entry for NCT03850379 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 308 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 165-participant average among 15 other Stem Cell Transplant Complications trials with a reported enrollment target (87% higher). The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stem Cell Transplant Complications appearing as the primary indexed condition, and to 2 interventions - of which Ciprofloxacin is the first listed.
NCT03850379 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT03850379 about?
NCT03850379 is a clinical study titled "Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant". Ciprofloxacin and levofloxacin are both in guidelines to use for prophylaxis in autologous and allogeneic Stem cell transplant.Ciprofloxacin was recently replaced by levofloxacin as the preferred agent in some transplant centers. In some small retrospective studies ciprofloxacin prophylaxis was asso...
What is the current status of trial NCT03850379?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 308 participants. The study started on 2018-03-14. Estimated completion is 2024-08-30.
What conditions does trial NCT03850379 study?
This clinical trial studies the following conditions: Stem Cell Transplant Complications, Prophylaxis.
What interventions are being tested in trial NCT03850379?
The interventions under investigation include: Ciprofloxacin (DRUG), Levofloxacin (DRUG).
Who is sponsoring clinical trial NCT03850379?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03850379 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stem Cell Transplant Complications
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
RECRUITING · Phase 2
-
A Double-blind Randomized Placebo Controlled Clinical Trial Evaluating Effect of Chlorhexidine Gluconate 2% Cloth vs Placebo Cloth Baths on the Incidence of Central Line-Associated Blood Stream Infections in Outpatient Hematopoietic Stem Cell Transplant Patients
COMPLETED · Phase 2
-
A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors
RECRUITING · NA
-
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
RECRUITING · NA
-
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
RECRUITING · Phase 3
-
Intestinal Microbiota in Stem Cell Transplant Transplant Admission
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.